Download PDF

1. Company Snapshot

1.a. Company Description

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing.The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions.The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973.


Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee.

Show Full description

1.b. Last Insights on DXR

Daxor Corporation's recent performance was driven by a series of strategic partnerships and clinical studies that showcased the efficacy of its blood volume analysis (BVA) technology. The company's ezBVA Lab service, a CLIA-certified facility, has been adopted by three new hospitals, expanding its reach and driving operational efficiency. Additionally, Daxor's BVA technology has been integrated into two new U.S. healthcare systems, further advancing the standard of care for cardiovascular and critical care patients. The company's innovative diagnostic solutions have also been recognized through a Duke University study published in the American Heart Journal, highlighting the value of BVA in identifying anemia in heart failure patients.

1.c. Company Highlights

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Card image cap

Daxor Fuels Growth with Three New Facility Adoptions and Deployment of Next-Generation BVA Analyzer

Nov -25

Source: globenewswire.com

Card image cap

Daxor CEO Michael Feldschuh to Engage Investors at Exclusive Maxim Growth Summit

Oct -21

Source: globenewswire.com

Card image cap

Daxor Unveils New FDA-Cleared BVA Analyzer Amid Strong Market Demand and Pivotal Clinical Data at HFSA

Sep -30

Source: globenewswire.com

Card image cap

Daxor Corporation Unveils Breakthrough Next-Gen BVA Analyzer at HFSA Annual Scientific Meeting

Sep -23

Source: globenewswire.com

Card image cap

Daxor's Blood Volume Analysis Validated for COVID and Sepsis Patients in New Peer-Reviewed Pilot Study Published in the Journal of Critical Care

Sep -04

Source: globenewswire.com

Card image cap

Daxor Corporation to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Sep -03

Source: globenewswire.com

Card image cap

Daxor Corporation CEO and President Michael Feldschuh Delivers 1st Half Corporate Update in Shareholder Letter

Sep -02

Source: globenewswire.com

Card image cap

Daxor Corporation Receives FDA Clearance for New Rapid, Lightweight, Blood Volume Analysis System

Aug -07

Source: globenewswire.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (10.20%)

6. Segments

Investment and Related Activities

Expected Growth: 10.2%

Daxor's Investment and Related Activities segment is poised for growth driven by increasing demand for marketable securities, trading securities, and other investments. The company's strategic investments in diversified portfolios and strong financial position will fuel growth, with a forecast CAGR of 10.2%.

7. Detailed Products

BVA-100 Blood Volume Analyzer

A diagnostic device that measures blood volume and vascular permeability, helping clinicians to diagnose and monitor various medical conditions such as heart failure, sepsis, and kidney disease.

Daxor Blood Volume Analysis Software

A software solution that analyzes data from the BVA-100 to provide accurate and reliable blood volume measurements.

Consulting and Training Services

Expert consulting and training services to help healthcare professionals optimize the use of Daxor's products and improve patient care.

8. Daxor Corporation's Porter Forces

Forces Ranking

Threat Of Substitutes

Daxor Corporation faces moderate threat from substitutes, as there are limited alternatives to blood transfusion products, but some hospitals may opt for alternative treatments.

Bargaining Power Of Customers

Daxor Corporation has a diverse customer base, and no single customer has significant bargaining power, reducing the threat of customer bargaining power.

Bargaining Power Of Suppliers

Daxor Corporation relies on a few key suppliers for raw materials, giving them some bargaining power, but the company's diversified supply chain mitigates this risk.

Threat Of New Entrants

The blood transfusion products market has high barriers to entry, including regulatory hurdles and significant capital requirements, making it difficult for new entrants to join the market.

Intensity Of Rivalry

The blood transfusion products market is highly competitive, with several established players competing for market share, leading to a high intensity of rivalry.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 2.17%
Debt Cost 3.95%
Equity Weight 97.83%
Equity Cost 1.68%
WACC 1.73%
Leverage 2.22%

11. Quality Control: Daxor Corporation passed 3 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
LeMaitre Vascular

A-Score: 4.8/10

Value: 1.2

Growth: 7.4

Quality: 7.0

Yield: 2.0

Momentum: 4.0

Volatility: 7.0

1-Year Total Return ->

View Full Report
Stock-Card
Warby Parker

A-Score: 4.5/10

Value: 3.3

Growth: 7.4

Quality: 4.1

Yield: 0.0

Momentum: 9.0

Volatility: 3.3

1-Year Total Return ->

View Full Report
Stock-Card
AtriCure

A-Score: 4.5/10

Value: 5.0

Growth: 6.0

Quality: 4.0

Yield: 0.0

Momentum: 7.5

Volatility: 4.3

1-Year Total Return ->

View Full Report
Stock-Card
Daxor

A-Score: 4.4/10

Value: 3.5

Growth: 6.7

Quality: 8.6

Yield: 0.0

Momentum: 4.5

Volatility: 3.3

1-Year Total Return ->

View Full Report
Stock-Card
Retractable Technologies

A-Score: 4.0/10

Value: 9.4

Growth: 0.6

Quality: 3.9

Yield: 0.0

Momentum: 6.5

Volatility: 3.7

1-Year Total Return ->

View Full Report
Stock-Card
Sanara MedTech

A-Score: 3.2/10

Value: 3.0

Growth: 6.8

Quality: 2.3

Yield: 0.0

Momentum: 4.0

Volatility: 3.0

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

1.12$

Current Price

12.85$

Potential

-91.29%

Expected Cash-Flows